
‘Why is Milton so poor?' A town of million-dollar homes struggles to pay its bills.
As a parent, you don't want your kids to worry about money, and for the most part, my kids haven't had to — until now.
The absurdity of it all is that Milton is not at all poor. Last year the median sale price of a single-family home in Milton was $1 million, and the median household income is nearly
Some of the school's fiscal problems have been self-inflicted —
Advertisement
'Communities that seem in many ways to be affluent, their city or town government may not be correspondingly affluent,' explained Adam Chapdelaine, executive director of the Massachusetts Municipal Association, an advocacy group for the state's 351 towns and cities.
Advertisement
And so, for the second time in a decade, Milton town officials are asking residents to vote to override Proposition 2½, the 1980 state law that restricts how much a municipality can increase its property tax collection.
Students board a school bus on Adams Street in East Milton for the morning ride to school in 2023. Milton Public Schools is now facing a projected budget deficit, and a tax override is needed to prevent deeper cuts and layoffs.
Lane Turner
Voters in a state-wide ballot initiative approved Prop. 2½ in a bid
to rein in out-of-control municipal spending, but decades later the concept has failed to keep up with expenses of modern times. School budgets, in particular, have gotten bigger to accommodate the growing number of students with disabilities that require costly services, from specialized therapies to one-on-one aides. Add in high energy prices and soaring costs of health insurance for town employees, and tax revenue hasn't kept pace with the bills.
Milton's hardly the only Boston-area suburb facing this predicament. Other towns from Brookline to Acton have faced similar financial challenges and have had to go to the ballot box in recent years to resolve budget shortfalls.
Related
:
During the pandemic years, federal money helped Milton and other towns put off raising taxes, but now those funds have run out. About 50 towns in Massachusetts held tax overrides last year, compared to an average of 24 override votes in the four years prior, according to an analysis by Chapdelaine.
He expects this year to be historically high for overrides. So much so that he thinks it's time policymakers consider whether the current municipal tax structure is sustainable.
'Prop. 2½ is under more strain than it's ever been,' said Chapdelaine. 'It's likely time for a dialogue around Prop. 2½'s efficacy as we try to maintain city and town services.'
Advertisement
I'm not happy about paying higher taxes, but I'll be voting yes Tuesday because Milton schools really can't afford to lose more. This would be the biggest override request in town history. But if it doesn't pass, the school system that serves about 4,300 students would have to slash school spending by about $6.3 million, or nearly 10 percent of its budget. That could mean a loss of 76 positions, including dozens of teachers and specialists, and cuts to clubs and sports.
Related
:
Supporting the override means my own property tax bill is estimated to go up by about $1,250 to about $15,000. That'll hurt
.
But it's a worthy investment in a town I love and have called home for 15 years. This is what it means to be part of a community. You come together in times of need. Plus, I want to pay it forward. Both of my sons are on the autism spectrum, and when they were in preschool and kindergarten, they benefited from Milton's specialized educational services — support that helped them become the high-functioning kids they are today.
In Medford, opponents of a tax override held Vote No Tax Overrides signs in 2024. The measures passed in November.
Cheryl Senter/Cheryl Senter for The Boston Globe
Mike Baker, a Milton resident who is an instructional aide at Pierce Middle School, will also be voting yes, but it still may not be enough to save his job. He's low on the seniority list at Milton's only middle school, and the override plugs future budget gaps, not the current one.
He's voting yes to ensure that his son, who is a sixth grader at Pierce with my son, will get a good education. Our kids also know each other from playing on the town's travel basketball team the past three seasons.
Advertisement
'We live in one of the richer towns in the state of Massachusetts and to have to even do a vote at all is kind of disheartening,' said Baker. Still, he calls the override a 'necessity.'
Despite Milton's affluence, it doesn't have much of a
commercial tax base, and that means residential property taxes are high. My tax bill is already close to double the state average of about $7,700.
Gulp again.
There's not a lot of new development to help absorb rising costs, either.
Of course, we could fix that part, but as the
with the state housing law — even after
Related
:
So will a 'yes' vote prevail?
Elizabeth Carroll, chair of the Milton School Committee, said she feels 'cautiously optimistic.' One indication: Drive around town, and you only see 'Vote Yes! For the Override' lawn signs. Supporters have been out in force, knocking on doors and even hosting an information session at a recent bingo lunch at the senior center.
'We don't have a visible 'no' campaign,' said Carroll. 'Other towns you see no signs. That makes me optimistic.'
Let's hope the signs have it right — and that Milton chooses to invest in its kids and its future.
Advertisement
Signs supporting a tax override are displayed in yards on Central Avenue in Milton. Residents head to the polls on Tuesday on whether to raise their property taxes.
Brett Phelps/Brett Phelps for The Boston Globe
Shirley Leung is a Business columnist. She can be reached at
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Live Blog: ICE protest at Texas Capitol
AUSTIN (KXAN) — A large crowd of people gathered at the Texas Capitol in Austin on Monday in solidarity with those protesting Immigration and Customs Enforcement actions in Los Angeles, according to organizers. A flyer posted to Instagram invited people to 'say 'ICE out of our cities! Stop the deportations!'' starting at 7 p.m. The post, from the Austin-area anti-capitalism group Party for Socialism and Liberation, was posted Sunday and called for an 'emergency protest.' Since Friday, thousands have taken to the streets in Los Angeles to protest after ICE agents arrested immigrants at a number of places in the city, as well as the deployment of National Guard troops in response to initial protests, according to the Associated Press. 8:30 p.m.: Law enforcement has started to pepper-spray protesters in the street on 9th and Congress. 8:27 p.m.: The crowd is now splitting into two groups. One group is walking again in the street. Another group is sticking around the Capitol. Our crew at the protest said the people in the street will get one more warning before being arrested. 8:21 p.m.: Law enforcement got on megaphones to tell people to move to the sidewalks because streets were opening back up. Some protesters are not obeying and yelling obscenities at law enforcement. 8:16 p.m.: The march is back at the Capitol grounds, and with the grounds closed, the crowd is gathering outside the gate. DPS has closed the intersection of 11th and Congress. The crowd is chanting, 'No more ICE!' 8:06 p.m.: The crowd is moving away from the federal building and is on Congress Avenue headed back toward the Capitol. 8 p.m.: According to an Austin Police Department post on X, the planned route of the march is as follows: South on Congress Ave. to 7th St. 7th St. to Trinity North on Trinity to 8th St. 8th St. back to Congress Ave. North on Congress Ave. to the Capitol The post said if you're driving in the area to be aware of the crowd. 7:57 p.m.: The march has stopped outside the federal building on 8th and San Jacinto. The crowd is now chanting, 'Whose streets? Our streets.' 7:54 p.m.: The march is turning on Trinity Street back toward the Capitol grounds. Texas DPS plans to have the grounds 'cleared and closed' at 8 p.m. 7:45 p.m.: 'The people, united, will never be defeated,' is the chant now. The group is walking down Congress Avenue. 7:38 p.m.: The crowd is beginning to march and is in the area of 11th and Congress. They are chanting, 'We will not put up with ICE. Say it once, say it twice.' 7:25 p.m.: KXAN's Grace Reader spoke with one of the people at the protest and said she decided to show up because she saw 'what was going on in Los Angeles,' and was 'very scared and upset about what our President is doing and using his power to turn the military against us.' 'They're on a hairpin trigger out there, and anything can set it off,' 67-year-old Lynn Tozser said. 'I don't want that to happen.' 7:10 p.m.: A unit of the DPS mounted patrol arrives at the Capitol grounds. Protest leaders said they do intend to march at some point. 7:05 p.m.: Protest leaders went over ground rules for the protest and told the crowd not to engage with 'instigators' or law enforcement. It appeared that Texas DPS troopers on bikes led someone who appeared to be counter-protesting away from the crowd. It didn't appear that DPS arrested the individual, at least from what the KXAN crew could see. 7 p.m.: KXAN has a crew at the Capitol grounds. The protest was scheduled to begin at 7 p.m. with 'dozens' of people there, but more were rapidly joining the protest. Texas DPS said the Capitol grounds will be 'cleared and closed' at 8 p.m. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
ROCKVILLE, Md. and SUZHOU, China, June 09, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that 13 studies of its core assets - including the novel drug olverembatinib (HQP1351), the investigational Bcl-2 inhibitor lisaftoclax (APG-2575), and the investigational EED inhibitor APG-5918 – will be featured in an oral presentation, multiple poster presentations and multiple online publications at the 2025 European Hematology Association (EHA) Annual Congress taking place in Milan, Italy, from June 12-15, 2025. The EHA Annual Congress is the largest gathering of the hematology community in Europe. Attracting more than 10,000 attendees from more than 100 countries every year, the congress showcases cutting-edge research and ground-breaking clinical results in the field of hematology. Oral PresentationIntegrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy Abstract#: S162 Session: Biology of CML treatment response and resistance Date and Time: Saturday, 14 June, 17:30-17:45 CEST / Saturday, 14 June, 23:30-23:45 Beijing Time Principal Authors: Prof. Qian Jiang, Peking University People's Hospital; Dr. Xiaoshuai Zhang, Peking University People's Hospital Poster PresentationsFrontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study Abstract#: PF384 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time Principal Author: Prof. Xiaowen Tang, The First Affiliated Hospital of Soochow University; Xin Zhang, The First Affiliated Hospital of Soochow University A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Abstract#: PF390 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Suning Chen, The First Affiliated Hospital of Soochow University; Wenzhi Cai, The First Affiliated Hospital of Soochow University Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia Abstract#: PS1367 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Hongsheng Zhou, Nanfang Hospital, Southern Medical University; Xiuli Xu, Nanfang Hospital, Southern Medical University Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial Abstract#: PS1372 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Jie Jin, The First Affiliated Hospital, Zhejiang University School of Medicine; Dr. Gaixiang Xu, The First Affiliated Hospital, Zhejiang University School of Medicine Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study Abstract#: PS1387 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Author: Erlie Jiang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Xiaoyu Zhang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models Abstract#: PS1993 Session: Lymphoma biology & translational research Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Principal Author: Dr. Eric Liang, Ascentage Pharma Group Inc. Online PublicationsAlternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis Abstract: PB2384 Principal Author: Prof. Zi-Yuan Nie, The Second Hospital of Hebei Medical University Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive/Negative B-Cell Acute Lymphoblastic Leukemia Abstract#: PB2363 Principal Author: Yinqiang Zhang, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Abstract#: PB2360 Principal Author: Xinwen Jiang, The Second Hospital of Hebei Medical University Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study Abstract#: PB2701 Principal Author: Mengyao Yuan, Peking University People's Hospital A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study Abstract#: PB2714 Principal Author: Tian Dong, West China Hospital of Sichuan University Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL) Abstract#: PB2341 Principal Author: Bo Peng, Ascentage Pharma (Suzhou) Co., Ltd. About Ascentage PharmaAscentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph+ ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML, and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma +86 512 85557777 Stephanie Carrington ICR Healthcare +1 (646) 277-1282 Media Relations: Sean Leous ICR Healthcare +1 (646) 866-4012Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Congressman Mark Green retiring from U.S. House of Representatives
NASHVILLE, Tenn. (WKRN) — Tennessee's 7th District Congressman, Mark Green, will retire from the U.S. House of Representatives, the federal lawmaker announced Monday. In a statement, Rep. Green announced he was retiring from Congressional service due to taking a private sector position that was 'too exciting to pass up.' Per his statement, Green has informed Speaker Mike Johnson (R-Louisiana) he will resign as soon as the House votes on the reconciliation package. 📧 Have breaking news come to you: → He called his time in Congress 'the honor of a lifetime,' touting 'historic tax cuts,' sweeping border security legislation and pro-life legislation as some of his proudest accomplishments in Washington. Green initially planned to exit public life at the end of his previous term, announcing last February he wouldn't seek a fourth term in office; however, he quickly backtracked just four weeks later. He easily defeated a challenge from former Nashville mayor Megan Barry in the Nov. 5, 2024, general election. Green's full statement reads as follows: It is with a heavy heart that I announce my retirement from Congress. Recently, I was offered an opportunity in the private sector that was took exciting to pass up. As a result, today I notified the Speaker of the House of Representatives that I will resign from Congress as soon as the House votes once again on the reconciliation package. It was the honor of a lifetime to represent the people of Tennessee in congress. They asked me to deliver on the conservative values and principles we all hold dear, and I did my level best to do so. Along the way, we passed historic tax cuts, worked with President Trump to secure the border, and defended innocent life. I am extremely proud of my work as Chairman of the Homeland Security Committee, and want to thank my staff, both in my seventh district office, as well as the professional staff on that committee. I have now served the public for nearly four decades. The Army took me to Iraq and Afghanistan. The people sent me to the Tennessee legislature and the halls of Congress. Along the way, I have often remarked on the strength of the men and women I have served with. I know that the integrity, decency, and faith of the American people are what powered us for the first 250 years, and will power us for another 250 and beyond. I can proudly look back at my time in Congress and the success that we have accomplished on behalf of Tennesseans and the American people. I am grateful to Speaker Johnson and House Leadership for placing their trust in me to chair the Committee on Homeland Security, lead the effort to impeach former Secretary Alejandro Mayorkas, and to pass H.R. 2, the Secure the Border Act, the strongest border security legislation in history to ever pass the House. However, my time in Congress has come to an end. Though I planned to retire at the end of the previous Congress, I stayed to ensure that President Trump's border security measures and priorities make it through Congress. By overseeing the border security portion of the reconciliation package, I have done that. After that, I will retire, and there will be a special election to replace me. I have no doubt that my colleagues in this Congress will continue to strengthen the cause of freedom. May God bless them, and the United States of America. Rep. Mark Green (TN-07) Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.